er, as a comparative effectiveness study, the reader is unable to assess how clinicians decided which test to order or what institutional protocols existed.
What disease or diseases were the clinicians trying to rule out? Why did they choose TRO CTA over a dedicated coronary CTA? Was it institutional protocol or provider choice? Furthermore, we do not know how many CTAs were done solely to evaluate for PE or aortic dissection.
Several questions that are clinically relevant should be raised by this study. Only 1 can really be addressed-whether coronary CTA and TRO CTA have similar diagnostic yields for coronary disease. This is the only disease that coronary CTA is designed to detect. The results of this study confirm that they are similar. Other highly relevant questions are the fol- Siemens, and Roche. Dr. Chang has reported that she has no relationships relevant to the contents of this paper to disclose. 
